Evidence map›Paper›PMID 33221872›Full record

ReviewClinical chemistry2021

HDL in Morbidity and Mortality: A 40+ Year Perspective.

Alan R Tall

Abstract readReview
In one paragraph

Review in Clinical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. The Role of High-Density Lipoprotein Cholesterol in 2022.Current atherosclerosis reports · 2022
    Review
  15. Addressing dyslipidemic risk beyond LDL-cholesterol.The Journal of clinical investigation · 2022
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Alan R TallDivision of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York City, NY.

Funding

Cholesterol efflux, CHIP and inflammasome activationR01HL107653 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ALAN richard TALL · 2011 to 2026
$7.7M
NHLBI NIH HHS R01 HL107653
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsATP Binding Cassette Transporter 1Cholesterol Ester Transfer ProteinsCholesterol, HDLCoronary DiseaseGenetic Association StudiesHumansImmunity, InnateLipoproteins, HDLLiver X ReceptorsNeoplasm ProteinsPolymorphism, Single NucleotideABCA1 protein, humanATP Binding Cassette Transporter 1Cholesterol Ester Transfer ProteinsCholesterol, HDLLipoproteins, HDLLiver X ReceptorsNeoplasm ProteinsTTC39B protein, human

Identifiers

PMID33221872
PMCPMC7793227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.